About Virax Biolabs
Advancing Immune Diagnostics for Chronic Inflammation and Immune Dysfunction.
Virax Biolabs is a Nasdaq-listed biotechnology company advancing immune-profiling technologies across research and diagnostics. Our lead diagnostics platform, ViraxImmune™, is initially being developed for post-acute infection syndromes, including Long COVID, with broader potential in immune monitoring and haemato-oncology as the platform evolves. Through ImmuneSelect, we also provide research-use products and services supporting T cell and immune-response profiling.
Meet Our Leadership
01
Clinical relevance
Focused on meaningful diagnostic gaps and reducing clinical uncertainty.
02
Scientific rigour
Grounded in T cell biology, structured evidence generation and certified quality systems.
03
Disciplined execution
Advancing development through defined clinical, regulatory and commercial milestones.
Leadership & scientific advisory board
Experienced Corporate
& Scientific Leadership.
Virax Biolabs is guided by an experienced management team, Board of Directors and Scientific Advisory Board, with expertise spanning biotechnology, diagnostics, clinical development, regulatory strategy and commercialisation.
COMBINED EXPERTISE
Corporate execution informed by scientific depth.
Leadership and advisory perspectives are structured to connect laboratory development, clinical evidence, regulatory planning, and commercial decision-making.
Molecular diagnostics
Regulatory strategy
Biotechnology commercialisation
Clinical trial design
Chief Executive Officer
James Foster
Leads Virax Biolabs with a focus on strategic growth, commercialisation, and long-term corporate development in the diagnostics space.
LinkedIn
Acting Chief Scientific Officer
Dr. Clement Monteil
Leads R&D efforts across the company, advancing the scientific development of ViraxImmune™ and related immune-profiling technologies.
LinkedIn
QUALITY ASSURANCE MANAGER
Kike Iwaye
Leads quality assurance and regulatory compliance, ensuring robust, ISO‑certified QMS frameworks across Virax Biolabs.
LinkedIn
Dr. Nigel McCracken
Provides independent operational and strategic perspective, drawing on broad biopharma leadership experience to support long‑term corporate planning.
LinkedIn
Independent Director
Dr. Iain Miller
Provides independent strategic oversight, supporting governance and long-term development across healthcare and life sciences.
Independent Director
Evan Norton
Contributes board-level expertise in strategy, governance, and business development as the company advances its commercial roadmap.
Independent Director
Nelson Haight
Brings independent oversight and strategic perspective to support financial, operational, and market-growth planning.
Advisory Board Member
Dr. Ailsa Snaith
Advises on scientific and clinical direction, helping strengthen the evidence base and translational relevance of the platform.
Advisory Board Member
Gordon Powell
Supports scientific development and innovation strategy, helping connect platform potential with clinical and commercial application.
Quality & regulatory strategy
World-Class Operational Standards.
Virax Biolabs operates quality management systems certified to ISO 9001:2015 and ISO 13485:2016. ViraxImmune™ is being advanced through a staged development strategy comprising active UK clinical validation, a planned US laboratory-developed test pathway subject to laboratory readiness and applicable requirements, and a potential longer-term FDA IVD pathway.
Development and launch timing remain subject to clinical evidence, regulatory engagement, quality-system readiness, and operational progress.
Quality system
ISO 9001 & ISO 13485 Certified
Current quality system maintained under ISO 9001 & ISO 13485 certification for medical devices.
2027 target
Planned US LDT Pathway
Preparation aligned with applicable laboratory, CMS, and CLIA requirements, subject to development progress.
2028+ target
FDA De Novo / IVD Pathway
A potential route toward broader regulatory authorisation following clinical and analytical validation.
PARTNER WITH US
Start a Conversation.
Contact our team regarding clinical studies, scientific collaboration, commercial partnerships, media or investor relations. Your inquiry will be directed to the appropriate team member at our BioCity headquarters.
01
Clinical Study-site and research inquiries02
Commercial Distribution and strategic alliances03
Corporate Media and investor-relations inquiries